secwatch / observer

8-K filed November 7, 2024, 6:59 PM ET ticker VERA CIK 0001831828

earnings confidence high sentiment neutral materiality 0.70

Vera Therapeutics reports Q3 net loss $46.6M, raises $345M; atacicept Ph3 enrollment done

Vera Therapeutics, Inc.

2024-Q3 EPS reported -$2.03

Net loss of $46.6M ($0.85/shr) vs $20.1M ($0.45) in Q3 2023; cash $353.3M as of Sept 30.
Completed $345M public equity offering to fund atacicept launch and regulatory submission.
Phase 3 ORIGIN 3 trial enrollment complete; topline data expected in Q2 2025.
Positive 96-week eGFR stabilization data from Phase 2 ORIGIN trial at ASN Kidney Week 2024.
Expanded atacicept development with PIONEER trial in broader IgAN and other kidney diseases.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-24-122814
form_type: 8-K
ticker: VERA
cik: 0001831828
company_name: Vera Therapeutics, Inc.
filed_at: 2024-11-07T23:59:59+00:00
discovered_at: 2026-05-14T18:03:09.905183+00:00
generated_at: 2026-05-30T03:48:39.243613+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-24-122814
json_url: https://secwatch.observer/filing/0000950170-24-122814.json
markdown_url: https://secwatch.observer/filing/0000950170-24-122814.md
text_url: https://secwatch.observer/filing/0000950170-24-122814.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1831828/000095017024122814/0000950170-24-122814-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1831828/000095017024122814/vera-20241107.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

IVF

INVO Fertility FY2025 revenue $6.84M (+5% YoY); net loss improves to $(5.3)M

INVO Fertility, Inc. June 2, 2026, 8:40 AM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

POLA

Polar Power Q1 net loss narrows 86% to $178K; gross margin expands to 65.7%

Polar Power, Inc. June 2, 2026, 8:30 AM ET earnings Items 2.02, 7.01, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

CTRN

Citi Trends Q1 sales up 14.4% to $230.9M; adjusted EBITDA doubles to $13.9M

Citi Trends Inc June 2, 2026, 6:58 AM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

SIG

Signet Q1 sales $1.6B, SSS +1.8%; raises FY27 adjusted EPS guidance

SIGNET JEWELERS LTD June 2, 2026, 6:54 AM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

Dollar General Q1 EPS $2.00 beats expectations; raises FY2026 EPS guidance

DOLLAR GENERAL CORP June 2, 2026, 6:54 AM ET earnings Items 2.02, 5.07, 7.01, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

HIVE

HIVE FY2026 revenue $297.8M (+158% YoY); GAAP net loss $148.4M

HIVE Digital Technologies Ltd. June 2, 2026, 6:23 AM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

DCI

Donaldson Q3 FY2026 sales $995.1M (+5.8%), adj. EPS $1.06 (+7.1%)

DONALDSON Co INC June 1, 2026, 5:41 PM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

GMRS

GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B

GMR Solutions Inc. June 1, 2026, 4:45 PM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0000950170-24-122814

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.